A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00134706
Recruitment Status : Completed
First Posted : August 25, 2005
Last Update Posted : December 9, 2009
Bristol-Myers Squibb
Beth Israel Deaconess Medical Center
Lowell General Hospital
Massachusetts General Hospital
Oregon Health and Science University
Wentworth-Douglass Hospital
Information provided by:
Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : April 2006
  Actual Study Completion Date : September 2009